Randomized Phase II Study of Nivolumab With or Without Ipilimumab in Patients With Metastatic or Unresectable Sarcoma

Trial Profile

Randomized Phase II Study of Nivolumab With or Without Ipilimumab in Patients With Metastatic or Unresectable Sarcoma

Recruiting
Phase of Trial: Phase II

Latest Information Update: 14 Oct 2017

At a glance

  • Drugs Nivolumab (Primary) ; Ipilimumab
  • Indications Gastrointestinal stromal tumours; Liposarcoma; Osteosarcoma; Soft tissue sarcoma
  • Focus Therapeutic Use
  • Most Recent Events

    • 03 Oct 2017 Status changed from suspended to recruiting.
    • 20 Jun 2017 Planned number of patients changed from 84 to 110.
    • 10 Jun 2017 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top